Chipiron
Chipiron is developing scalable MRI technologies with the goal of making MRI 100x more accessible to enable widespread early diagnosis and image-guided therapies for deadly diseases. Their innovative approach leverages ultra-low magnetic fields (<10 mT) to create a light, inexpensive, open full-body MRI machine without compromising image quality. Key technological advancements include a patented low-Tc SQUID volume gradiometer for improved SNR, an AI noise cancellation system, an MRI-compatible cryostat for an ultra-light cooling system, and unconventional low-field AI reconstruction techniques to reduce acquisition times. Chipiron has secured significant funding, including a $17M Series A, and has received grants from EIC Accelerator and France 2030. They were recognized with the 'Innovation of the Year' award at VivaTech 2025 by TechCrunch. Their roadmap includes prototyping in August 2024, achieving clinical-grade image quality by November 2025, and targeting FDA submission by September 2026. The company aims to make MRI as common as blood sampling.
Chipiron
Chipiron is developing scalable MRI technologies with the goal of making MRI 100x more accessible to enable widespread early diagnosis and image-guided therapies for deadly diseases. Their innovative approach leverages ultra-low magnetic fields (<10 mT) to create a light, inexpensive, open full-body MRI machine without compromising image quality. Key technological advancements include a patented low-Tc SQUID volume gradiometer for improved SNR, an AI noise cancellation system, an MRI-compatible cryostat for an ultra-light cooling system, and unconventional low-field AI reconstruction techniques to reduce acquisition times. Chipiron has secured significant funding, including a $17M Series A, and has received grants from EIC Accelerator and France 2030. They were recognized with the 'Innovation of the Year' award at VivaTech 2025 by TechCrunch. Their roadmap includes prototyping in August 2024, achieving clinical-grade image quality by November 2025, and targeting FDA submission by September 2026. The company aims to make MRI as common as blood sampling.
TL;DR
Product: Ultra-low-field (<10 mT) full-body portable MRI using SQUID detectors and lightweight cryostat
Mission: Make MRI ~100x more accessible for early diagnosis and image-guided therapies
Funding: Raised a $17M Series A (Apr 30, 2025) plus multiple public grants (EIC Accelerator, France 2030)
HQ & founding: Paris, France; founded 2020
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |